Calquence is available in two formulations: immediate-release capsules and an oral suspension [1]. The immediate-release formulation was approved by the U.S. Food and Drug Administration (FDA) in October 2019 [1][2]. In January 2022, the FDA also approved an oral suspension of Calquence, offering an alternative administration route [1][3].
What is the difference between Calquence capsule and suspension formulations?
The primary difference lies in their administration. Calquence is available as immediate-release capsules taken orally, and as an oral suspension, also taken orally [1]. Both formulations contain the active ingredient acalabrutinib [1].
What is Calquence used for?
Calquence (acalabrutinib) is a prescription medication used to treat adults with mantle cell lymphoma (MCL) who have received at least one prior therapy [1]. It is also used for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [1].
How does Calquence work?
Calquence is a type of drug called a Bruton's tyrosine kinase (BTK) inhibitor. BTK is a protein that plays a role in the growth and survival of certain white blood cells, including malignant B-cells [1]. By inhibiting BTK, acalabrutinib helps to control the proliferation of these cells [1].
When can new formulations of drugs like Calquence be developed?
The development of new formulations, such as an oral suspension, typically occurs after the initial drug approval. Pharmaceutical companies may pursue new formulations to improve patient convenience, address specific patient populations (e.g., those with difficulty swallowing), or to potentially extend market exclusivity.
Are there any patent concerns for Calquence?
Information regarding the specific patent landscape and potential patent challenges for Calquence is available through specialized patent tracking services [4].
Who manufactures Calquence?
Calquence is manufactured by AstraZeneca [1].
What are the side effects of Calquence?
Common side effects of Calquence include diarrhea, fatigue, muscle pain, bruising, and rash [1]. More serious side effects can involve bleeding, infections, heart rhythm changes, and low blood cell counts [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
Where can I find more information about Calquence formulations?
Detailed information about Calquence, including its formulations and prescribing information, can be found on the drug's official website and through the FDA's drug database [1][2][3].
How long does Calquence treatment typically last?
The duration of Calquence treatment depends on the specific condition being treated and the patient's response to the medication, as determined by their healthcare provider [1].
Sources:
[1] https://www.calquence.com/
[2] https://www.fda.gov/drugs/new-drugs-fda-cders- novedades-and-approvals/fda-approves-calquence-acalabrutinib-treatment-mantle-cell-lymphoma
[3] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-certifications
[4] https://drugpatentwatch.com/